1. Home
  2. PRE vs TLSI Comparison

PRE vs TLSI Comparison

Compare PRE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$19.86

Market Cap

295.3M

Sector

Industrials

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$3.17

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRE
TLSI
Founded
2014
2010
Country
Hong Kong
United States
Employees
285
102
Industry
Biotechnology: Laboratory Analytical Instruments
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.3M
270.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRE
TLSI
Price
$19.86
$3.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$30.50
$7.00
AVG Volume (30 Days)
277.9K
754.8K
Earning Date
06-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$108.69
$35.45
Revenue Next Year
$58.68
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$2.20
52 Week High
$23.63
$7.95

Technical Indicators

Market Signals
Indicator
PRE
TLSI
Relative Strength Index (RSI) 57.45 41.31
Support Level $12.92 $2.20
Resistance Level $21.72 $5.41
Average True Range (ATR) 1.66 0.30
MACD 0.45 0.03
Stochastic Oscillator 73.33 50.96

Price Performance

Historical Comparison
PRE
TLSI

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: